Literature DB >> 2511243

Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis.

F G Roberge1, H Lorberboum-Galski, P Le Hoang, M de Smet, C C Chan, D Fitzgerald, I Pastan.   

Abstract

A characteristic of activated T lymphocytes is the expression of high affinity IL-2R. We studied a new method of selective immunosuppression directed against activated T cells by using a chimeric recombinant protein (IL-2-PE40) composed of IL-2 fused to a modified Pseudomonas exotoxin lacking its cell recognition domain. As a model of T cell-mediated disease, we used experimental autoimmune uveoretinitis (EAU) produced in Lewis rats by active immunization with the retinal S-Ag. The treatment protocol consisted of i.p. injection of IL-2-PE40 at 0.25 micrograms/g every 12 h. Controls were PBS, PE40, or IL-2-PE40asp553 a mutant form of the molecule with reduced activity. Treatment with IL-2-PE40 resulted in a significant reduction of the incidence and severity of EAU over controls. The analysis of the effect of i.p. injection of IL-2-PE40 on the popliteal draining lymph nodes of immunized animals showed a marked reduction in the lymphocytes content. Transfer experiments demonstrated that IL-2-PE40 prevented the development of EAU effector T cells. Interestingly, although activated B cells were reported to express IL-2R, there was no significant reduction of antibody production against the immunizing Ag under IL-2-PE40 treatment, suggesting sparing of the B cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  7 in total

Review 1.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.

Authors:  Michael J Segel; Rami Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

Review 3.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

4.  Molecular chimerization of Pasteurella haemolytica leukotoxin to interleukin-2: effects on cytokine and antigen function.

Authors:  H P Hughes; M Campos; A A Potter; L A Babiuk
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

5.  Identification of a pathogenic epitope involved in initiation of Heymann nephritis.

Authors:  D Kerjaschki; R Ullrich; K Diem; S Pietromonaco; R A Orlando; M G Farquhar
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Prevention of experimental autoimmune uveoretinitis and experimental autoimmune pinealitis in (Lewis x Brown-Norway) F1 rats by HgCl2 injections.

Authors:  A Saoudi; B Bellon; Y de Kozak; J Kuhn; M C Vial; B Thillaye; P Druet
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

Review 7.  Immunotherapeutic strategies in autoimmune uveitis.

Authors:  Pedro Henrique Papotto; Eliana Blini Marengo; Luiz Roberto Sardinha; Anna Carla Goldberg; Luiz Vicente Rizzo
Journal:  Autoimmun Rev       Date:  2014-05-12       Impact factor: 9.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.